CN Patent

CN113905761A — 治疗驱动基因阳性肺癌的联用药物组合物

Assigned to Chia Tai Tianqing Pharmaceutical Group Co Ltd · Expires 2022-01-07 · 4y expired

What this patent protects

治疗驱动基因阳性肺癌的联用药物组合物，其包括抗PD‑L1抗体和安罗替尼，其具有良好的抗驱动基因阳性肺癌活性。

USPTO Abstract

治疗驱动基因阳性肺癌的联用药物组合物，其包括抗PD‑L1抗体和安罗替尼，其具有良好的抗驱动基因阳性肺癌活性。

Drugs covered by this patent

Patent Metadata

Patent number
CN113905761A
Jurisdiction
CN
Classification
—
Expires
2022-01-07
Drug substance claim
No
Drug product claim
No
Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.